Population Pharmacokinetics of TAK‐931, a Cell Division Cycle 7 Kinase Inhibitor, in Patients With Advanced Solid Tumors-Reference-Cited by-同舟云学术

Population Pharmacokinetics of TAK‐931, a Cell Division Cycle 7 Kinase Inhibitor, in Patients With Advanced Solid Tumors

Published:2021-10-26 Issue: Volume: Page:
ISSN:0091-2700
Container-title:The Journal of Clinical Pharmacology
language:en
Short-container-title:The Journal of Clinical Pharmacology

Author:

Zhou Xiaofei¹,Ouerdani Aziz²,Diderichsen Paul Matthias³,Gupta Neeraj¹

Affiliation:

1. Millennium Pharmaceuticals, Inc., Cambridge, MA, USA, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited Cambridge Massachusetts USA

2. Certara Data Science Services Paris France

3. Certara Data Science Services Breda The Netherlands

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/jcph.1974

Reference30 articles.

1. Cdc7‐Dbf4 kinase overexpression in multiple cancers and tumor cell lines is correlated with p53 inactivation;Bonte D;Neoplasia,2008

2. Targeting cell division cycle 7 kinase: a new approach for cancer therapy;Montagnoli A;Clin Cancer Res,2010

3. High expression of cell division cycle 7 protein correlates with poor prognosis in patients with diffuse large B‐cell lymphoma;Hou Y;Med Oncol,2012

4. CDC7 kinase is a predictor of survival and a novel therapeutic target in epithelial ovarian carcinoma;Kulkarni AA;Clin Cancer Res,2009

5. CDC7 overexpression is an independent prognostic marker and a potential therapeutic target in colorectal cancer;Melling N;Diagn Pathol,2015

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Identifying CDC7 as a synergistic target of chemotherapy in resistant small-cell lung cancer via CRISPR/Cas9 screening;Cell Death Discovery;2023-02-02

2. Safety, Tolerability, and Pharmacokinetics of TAK-931, a Cell Division Cycle 7 Inhibitor, in Patients with Advanced Solid Tumors: A Phase I First-in-Human Study;Cancer Research Communications;2022-11-14

3. CDC7 as a novel biomarker and druggable target in cancer;Clinical and Translational Oncology;2022-06-03

4. Assessment of Effects of Investigational TAK‐931, an Oral Cell Division Cycle 7 Kinase Inhibitor on the QTc Intervals in Patients With Advanced Solid Tumors;Clinical Pharmacology in Drug Development;2022-02-20